BSc (Hons), MBBS (Hons) MEd MRCP
Novo Nordisk Clinical Research Training Fellow & DPhil Student
I am a Specialist Registrar and Clinical Research Fellow in Diabetes, Endocrinology and Metabolism.
My undergraduate training was undertaken at Imperial College London from where I hold a BSc in Pharmacology and Toxicology and graduated in Clinical Medicine with Distinction.
As part of my postgraduate medical training, I was awarded competitive NIHR Academic Clinical Fellowships at Imperial College London and at Bart’s and the London School of Medicine through which I have pursued research in obesity, metabolism and fatty liver disease, alongside my clinical practice. I also have considerable experience in medical education and clinical leadership and hold a Master’s in Education (MEd). Between 2010-11, I worked on secondment at the Department of Health as a Clinical Advisor to the National Medical Director for the NHS in England where my portfolio included work on quality improvement and clinical leadership within the NHS.
My research is focused on non-alcoholic fatty liver disease (NAFLD), which is becoming the most common cause of chronic liver disease worldwide and affects up to 70% of patients with Type 2 Diabetes. Firstly, I have established a clinical trial to investigate the utility of GLP-1 agonists as novel therapeutic agents to treat patients with NAFLD, which includes the use of stable isotope tracers and magnetic resonance imaging to evaluate outcomes. In addition, I am investigating the use of the urinary steroid metabolome as a novel non-invasive diagnostic tool with which to diagnose and stage NAFLD and to track treatment response.
The effect of metformin on hepatic fatty acid partitioning; an investigation using human in vivo and in vitro models
Green C. et al, (2019), JOURNAL OF HEPATOLOGY, 70, E794 - E795
SGLT2 inhibition does not reduce hepatic steatosis in overweight, insulin resistant patients without type 2 diabetes
Marjot T. et al, (2019), JOURNAL OF HEPATOLOGY, 70, E68 - E68
Mapping tissue water T1 in the liver using the MOLLI T1 method in the presence of fat, iron and B0 inhomogeneity.
Mozes FE. et al, (2019), NMR Biomed, 32
A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health
Moolla A. et al, (2019), Frontline Gastroenterology
Liver biochemical abnormalities in Turner syndrome: A comprehensive characterization of an adult population.
Calanchini M. et al, (2018), Clin Endocrinol (Oxf), 89, 667 - 676